Member Info for Energyshares

12 trading days left in November

For full impact on media Avacta shouldn’t release data on these dates:

Inflation figures 15th Nov

Autumn Budget 22nd Nov

Black Friday 24th Nov

So if not this week

Doesn’t look likely next week

So my guess last week in November W/C 27th Nov

Come Avacta Welease Wodger

GLA…

Dr Eliot Forster, Chairman of Avacta Group plc added:

"Targeting of cancer therapies to tumour tissue has been a long sought after goal for many oncology drug companies, clinicians and patients. There are many potent anti-cancer drugs, the effectiveness of which is limited by the systemic toxicities and lack of tolerability for patients.

Well the many will start knocking soon….

“Avacta couldn’t spell it out any clearer, but still the trolls keep trying to spin negativity”

Why put “Revolutionising

the treatability of solid tumours” on a massive screen outside your office

If it didn’t work ?

Why does CEO state in a RNS

“One patient with soft tissue sarcoma has shown a significant reduction in tumour volume in response to the drug”

If it didn’t work ?

Why does CEO states in a RNS

"I believe that we are on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients.”

If it didn’t work?

Why does the CEO answer when asked about future funding :

“don’t you worry about that”

If it didn’t work ?

Why does the Consultant Chief Medical Officer state in a RNS

"We have potential to exploit AVA6000 to treat other cancers such as breast and ovarian and a wealth of opportunities to build our pipeline and partnerships.

If it didn’t work ?

Why does the Chairman of Avacta Group states in a RNS

"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.”

If it didn’t work ?

Why did Shaun Chilton join the board as Non-Executive Director

If it didn’t work ?

Why did Dr William Tap choose to work with a tiny Aim Biotech in Avacta and not accept larger rewards from BP

If it didn’t work ?

Why have the MHRA & FDA approved 7 cohorts with potential fatal doses of Dox

If it didn’t work ?

Why have Avacta concluded that a phase 1B is no longer required and will move straight to phase 2 and is on record as saying it works…

If it didn’t work ?

Avacta couldn’t spell it out any clearer, but still the trolls keep trying to spin negativity.

Hold on to your shares and wait for PK data for your rewards ….. GLA

This is why Avacta’s Pre/Cision platforms PK data will be on every BP board room table in the very near future.

AS and the Avacta board have played a blinder with timing of AVA6000.

According to Precedence Research, the global oncology market size worth at US$ 203.42 billion in 2022 and is predicted to reach over US$ 470.61 billion by 2032.

GLOBOCAN, has stated that approximately 19.3 million new cancer cases and about 10 million deaths related to cancer were recorded in 2020, across the globe. The IARC has estimated that the new cancer cases are expected to rise by 47% all over the globe from 2020 to 2040.

North America accounted for around 46% of the market share in 2022 and dominated the global oncology market.

https://www.precedenceresearch.com/oncology-market

Eliot Forster non executive chairman of Avacta became Protalix Bio Chairman mid September 2023.

Three weeks later Israel are at war.Just hope he stays safe in his new role:

Top man.

https://www.nasdaq.com/articles/protalix-biotherapeutics-appoints-eliot-richard-forster-to-succeed-zeev-bronfeld-as

https://protalixbiotherapeutics.gcs-web.com/node/13746/pdf

https://protalix.com/

Could a certain BP who may be running their eyes over Avacta and the Pre/Cision platform and all of Avacta’s other IP,be ready to trump Eli Lilly in the Point Bio deal.

Do they want all Pre/Cision licences under their control.

Pop corn ready it’s going to be a good Christmas ….

GLA…

Https://seekingalpha.com/news/4031202-point-biopharma-quickly-gains-as-big-holder-comes-out-against-eli-lilly-deal

Thanks Gmcc

This link better

Biotechnology Value Fund sees "negligible downside and the potential for significant upside for the issuer’s shareholders to await the results of the SPLASH Study prior to consummating the Acquisition," the investor said in the filing. "Accordingly, in the absence of the SPLASH Study results, the Reporting Persons do not intend to tender their Shares in support of the Acquisition in the initial tender period expiring November 9, 2023."

Plus they have pre/Cision licence also waiting on Q4 data

This is very interesting pod cast 18 mins in

Break through therapy harder to achieve than fast track.

FDA give a lot of guidance Avacta must be close to approval once they have PK data ready.

GLA…..

https://m.youtube.com/watch?v=U0kmxYRQQS0&feature=youtu.be

Well worth a watch

https://m.youtube.com/watch?v=ae2xENSTp4Y&pp=ygUOZHIgd2lsbGlhbSB0YXA%3D

GLA…

🦒to keep this thread going

This puts Eggy argument to bed:

18 mins in:

https://youtu.be/PWrjyiR-r6o?si=YEIBi-o-HXDkgg9L

Courtesy of @blueberrymgmnt from X (twitter)

Https://clinicaltrials.gov/study/NCT04969835?tab=history&a=1

SP still under £1.50 just buy now

Eggy if arthritis was a problem it would be listed on this here:

Key Exclusion Criteria:

Received trastuzumab within 7 months of the planned Cycle 1, Day 1 AVA6000 infusion

Received a prior total cumulative anthracycline dose of >350mg/m^2 doxorubicin hydrochloride (or equivalent anthracycline dose)

Clinically significant or untreated central nervous system (CNS) metastases requiring treatment, as determined by the Investigator.

Has leptomeningeal disease

Any history of an active (requiring treatment) other malignancy (except any in-situ carcinoma, non-melanoma skin carcinoma and early prostate cancer with a normal PSA) within 2 years of study entry

Has a significant, uncontrolled, concomitant disease that could affect compliance with the protocol

Has uncontrolled hypertension (systolic blood pressure [SBP] >150 mmHg and/or diastolic [DBP] >100 mm Hg), unstable angina, congestive heart failure (New York Heart Association (NYHA) Class >II), left ventricular ejection fraction (LVEF)

FAP in joints I think you need to find a new dealer 😂

“You're twisting my melon man”

Rampers & trolls will be here until BP turn up but let the banter carry on.

Give it learn to take it…..

Not saying meeting didn’t happen.

The meeting notes sound convincing, but 350 members claim they own 16% of the company.

Avacta share capital = 283,614,110 shares

16% of company = 45,378,257

350 TG members average 129,652 shares each.

I can’t see each member of the group holding that amount.

So the magnificent 7 who attended must hold very large holdings hence the private meeting.

GLA

In my opinion it’s got to be a licence deal very soon.

Avacta BOD would not rush out PK Data for a BP to buy the company.

They would rush out PK data to secure a licence agreement to secure the companies future.

Earlier in the year AS,We will release data after P1a complete, now we will release C6 data with some C7 if available.

New buzz word optionality.

What does that mean

A 100m upfront licence deal

Allows AVA6000 to be brought to market with a equal revenue BP partner

Could pay off HCI loan if required

Allows more Pre/Cision drugs to be moved forward.

Dream outcome a BP takes multiple licences on platform.

That would rattle the rest of BP.

GLA

It’s a bit of a coincidence since Eli Lilly announced they were buying Point Bio ( the only company with a Pre/Cision licence)

Avacta daily traded volume has more than doubled since last quarter.

Who is buying ????